Kura Oncology is trading 5.27% down now at $9.34, amid broader biotech weakness; no verified company-specific announcement on October 23, 2026 explains the decline. - Biotech is down 2.08% during the session; the Dow is down 1.28% and the S&P 500 is down 0.47%, pointing to sector weakness and cautious market sentiment. - A recent report of a $100 million offering filing does not establish it as the cause.